Patient-specific stem cells and cardiovascular drug discovery

JAMA

Volumn 310, Issue 19, 2013, Pages 2039-2040

  Mordwinkin, Nicholas M ^a   Lee, Andrew S ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBRYONIC STEM CELL; GENE EXPRESSION; GENETIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART ARRHYTHMIA; HUMAN; NANOG GENE; NONHUMAN; OCT4 GENE; ONCOGENE C MYC; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SHORT SURVEY; SOMATIC CELL; SOX2 GENE; TRANSGENE;

EID: 84887949485     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282409     Document Type: Short Survey

References (9)

1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.
2. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214.
3. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.
4. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012;10(1):16-28.
5. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013;138(3):470-484.
6. Abassi YA, Xi B, Li N, et al. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol. 2012;165(5):1424-1441.
7. Taylor AL, Ziesche S, Yancy C, et al African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057.
8. Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127(16):1677-1691.
9. Paul SM, Lewis-Hall F. Drugs in search of diseases. Sci Transl Med. 2013;5(186):86fs18.